[go: up one dir, main page]

WO2010097115A1 - Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol - Google Patents

Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol Download PDF

Info

Publication number
WO2010097115A1
WO2010097115A1 PCT/EP2009/052306 EP2009052306W WO2010097115A1 WO 2010097115 A1 WO2010097115 A1 WO 2010097115A1 EP 2009052306 W EP2009052306 W EP 2009052306W WO 2010097115 A1 WO2010097115 A1 WO 2010097115A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
treatment
product
pharmaceutical formulation
oxy
Prior art date
Application number
PCT/EP2009/052306
Other languages
French (fr)
Inventor
Darrell Baker
Mark Bruce
Marian Thomas
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40547825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010097115(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to LTEP19175120.5T priority Critical patent/LT3578169T/en
Priority to DK09779096.8T priority patent/DK2400950T3/en
Priority to DK19175120.5T priority patent/DK3578169T3/en
Priority to ES09779096T priority patent/ES2739352T3/en
Priority to HUE19175120A priority patent/HUE067290T2/en
Priority to ES19175120T priority patent/ES2994042T3/en
Priority to PL09779096T priority patent/PL2400950T3/en
Priority to PL19175120.5T priority patent/PL3578169T3/en
Priority to US13/148,982 priority patent/US11116721B2/en
Priority to EP09779096.8A priority patent/EP2400950B1/en
Priority to PT09779096T priority patent/PT2400950T/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to PCT/EP2009/052306 priority patent/WO2010097115A1/en
Priority to EP19175120.5A priority patent/EP3578169B1/en
Priority to JP2011551415A priority patent/JP5809985B2/en
Priority to SI200931991T priority patent/SI2400950T1/en
Priority to HRP20241000TT priority patent/HRP20241000T3/en
Priority to HUE09779096A priority patent/HUE045917T2/en
Priority to EP24179210.0A priority patent/EP4403231A3/en
Priority to FIEP19175120.5T priority patent/FI3578169T3/en
Priority to PT191751205T priority patent/PT3578169T/en
Priority to LTEP09779096.8T priority patent/LT2400950T/en
Priority to SI200932199T priority patent/SI3578169T1/en
Publication of WO2010097115A1 publication Critical patent/WO2010097115A1/en
Priority to HRP20191257TT priority patent/HRP20191257T1/en
Priority to CY20191100870T priority patent/CY1121914T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • This invention relates to pharmaceutical products and compositions for use in treating diseases mediated via the beta-2 adrenoreceptor, for example in the treatment and/or prophylaxis of respiratory diseases. More particularly this invention relates to novel compositions of the compound 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6- dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol and pharmaceutically acceptable salts thereof and combinations thereof with other therapeutic agents, in particular 6 ⁇ ,9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ - hydroxy-16 ⁇ -methyl-3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (fluticasone furoate), and the use of said compositions and combinations in medicine, particularly in the treatment of asthma and related disorders, such as the treatment of chronic obstructive pulmonary disease (COPD).
  • Selective beta-2 adrenoreceptor agonists have been used in the prophylaxis and treatment of clinical conditions for which a bronchodilating agent has been indicated.
  • Such conditions include diseases associated with airflow obstruction such as asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic and whez bronchitis, emphysema), respiratory tract infection and upper respiratory tract disease (e.g. rhinitis, including seasonal and allergic rhinitis).
  • COPD chronic obstructive pulmonary diseases
  • rhinitis e.g. chronic and whez bronchitis, emphysema
  • respiratory tract infection e.g. rhinitis, including seasonal and allergic rhinitis.
  • beta-2 adrenergic receptor agonists beta-2 adrenergic receptor agonists
  • beta-2 agonists beta-2 adrenergic receptor agonists
  • short acting compounds for immediate relief such as salbutamol, biltolterol, pirbuterol and terbutaline.
  • longer acting compounds such as salmeterol and formoterol.
  • salmeterol and formoterol are effective bronchodilators, in general their duration of action in human subjects is around 12 hours, hence twice daily dosing is generally required.
  • beta-2 agonists provide for symptomatic relief of bronchoconstriction in patients
  • another component of asthma i.e. inflammation
  • this treatment has been with a steroid.
  • corticosteroids for use include beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, mometasone furoate and triamcinolone.
  • WO 03/024439 describes compounds of the general formula:
  • the compound 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6-dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 - hydroxyethyl ⁇ -2-(hydroxymethyl)phenol is specifically described in WO03/024439, as are pharmaceutically acceptable salts thereof, in particular the acetate, thphenylacetate, ⁇ -phenylcinnamate, 1 -naphthoate and (R)-mandelate salts.
  • WO02/12265 discloses the compound 6 ⁇ , 9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]- 11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S- fluoromethyl ester.
  • the present invention provides a novel pharmaceutical formulation comprising a dry powder formulation of 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6- dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol:
  • Compound (I) may refer to the free base depicted above, and/or one or more salts thereof, as dictated by the context.
  • Compound (I) may exist in enantiomerically pure form or as a mixture of isomers, e.g. a racemic mixture.
  • Compound (I) is 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6- dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol triphenylacetate.
  • Compound (I) is 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6- dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol ⁇ - phenylcinnamate.
  • the present invention provides a pharmaceutical product comprising: - -
  • a pharmaceutical formulation comprising 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6- dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof (Compound I), a carrier such as lactose and a ternary agent such as magnesium stearate; and b) 6 ⁇ , 9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo- androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester
  • This invention also provides for use of said pharmaceutical formulation and/or said pharmaceutical product in the manufacture of a medicament for the treatment and/or prophylaxis of respiratory diseases.
  • the use is for the manufacture of a medicament for the treatment of asthma and/or chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the invention also provides said pharmaceutical formulation and/or said pharmaceutical product for use in the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, such as asthma and/or chronic obstructive pulmonary disease (COPD).
  • inflammatory or respiratory tract diseases such as asthma and/or chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Another embodiment of the invention is a method for the treatment and/or prophylaxis of respiratory diseases, comprising administering to a patient in need thereof said - -
  • compositions or said pharmaceutical product comprising Compound (I) and Compound (II) wherein Compound (I) and Compound (II) are administered either sequentially or simultaneously.
  • the respiratory disease is selected from the group consisting of chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
  • the present invention is directed to a pharmaceutical product comprising:
  • the present invention provides a novel formulation comprising 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6-dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2- (hydroxymethyl)phenol: - -
  • Compound I a pharmaceutically acceptable salt thereof (Compound I), a carrier such as lactose and a ternary agent such as magnesium stearate.
  • Said formulation is suitable for topical delivery to the lung by inhalation, and may be administered by inhalation via the nose or mouth.
  • Formulations of Compound (I) with lactose and magnesium stearate have been found to demonstrate good levels of physical and chemical stability of the product, including at lower product strengths.
  • Said formulation may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the active ingredient into association with said carrier and ternary agent. Thus the formulations may be prepared by uniformly and intimately bringing into association Compound (I) with lactose and magnesium stearate. The formulation may be if desired filled into suitable unit dose forms.
  • Compound (I) is generally present in an amount of 0.020 - 3.0%, e.g. 0.024-0.8% by weight of the formulation wherein the weight of Compound (I) is calculated as the free base.
  • Medicaments for administration by inhalation desirably have a controlled particle size.
  • the optimum particle size for inhalation into the bronchial system is usually 1 -1 O ⁇ m, preferably 2-5 ⁇ m. Particles having a size above 20 ⁇ m are generally too large when inhaled to reach the small airways.
  • the particles of the active ingredient as produced may be size reduced by conventional means e.g. by micron ization.
  • the desired fraction may be separated out by air classification or sieving.
  • the particles will be crystalline.
  • the carrier e.g. lactose generally forms from 94 -99%, e.g. 97.7 - 99.0% by weight of the formulation.
  • the particle size of the carrier for example lactose
  • the carrier will typically be present as milled lactose, wherein not more than 85% of lactose particles will have a MMD (mass median diameter) of 60-90 ⁇ m and not more than 15% will have a MMD of less than 15 ⁇ m.
  • the lactose is anhydrous lactose or lactose monohydrate.
  • Magnesium stearate is generally present in an amount of 0.2 to 2%, e.g. 0.6 to 2%%, e.g. 0.75%, 1 %, 1.25% or 1.5%.
  • the magnesium stearate will typically have a particle size in the range 1 to 50 ⁇ m, and more particularly 1 - 20 ⁇ m, e.g.1 -10 ⁇ m.
  • stearic acid may comprise a mixture of stearic and palmitic acids; small amounts of other acids, e.g., lauric acid, myristic acid and/or arachic acid may also be present.
  • magnesium stearate similarly may comprise a mixture of salts formed with said acids.
  • the proportion of stearic acid present is 40.0 to 100%.
  • the proportion of stearic acid is present in an amount from 60 to 75% with the total proportion of stearic and palmitic acids in an amount from 90-100% e.g. 96-100%.
  • the aforesaid formulations comprise Compound (I), lactose and magnesium stearate.
  • the aforesaid formulations consist of Compound (I), lactose and magnesium stearate. - -
  • Pharmaceutically acceptable acid addition salts of Compound (I) include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, thfluoroacetic, triphenylacetic, phenylacetic, substituted phenyl acetic e.g., methoxyphenyl acetic, sulphamic, sulphanilic, succinic, oxalic, fumaric, maleic, malic, glutamic, aspartic, oxaloacetic, methanesulphonic, ethanesulphonic, arylsulphonic (for example p-toluenesulphonic, benzenesulphonic, naphthalenesulphonic or naphthalenedisulphonic), salicylic, glutahc, gluconic, tricarballylic, mandelic, cinnamic, substituted cinnamic (for example,
  • the pharmaceutically acceptable salt of Compound (I) is selected from the acetate, 1 -naphthoate and (R)-mandelate salts.
  • the pharmaceutically acceptable salt of Compound (I) is the ⁇ -phenylcinnamate salt.
  • the pharmaceutically acceptable salt of Compound (I) is the triphenylacetate salt.
  • the invention provides a novel pharmaceutical formulation comprising 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6-dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 - hydroxyethyl ⁇ -2-(hydroxymethyl)phenol triphenylacetate, lactose and magnesium stearate.
  • the invention provides a novel pharmaceutical formulation consisting of 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6-dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 - hydroxyethyl ⁇ -2-(hydroxymethyl)phenol thphenylacetate, lactose and magnesium stearate.
  • the invention provides a novel pharmaceutical formulation comprising 0.03-0.04% 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6-dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]- 1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol triphenylacetate, 94 -99%, lactose and 0.75 - 1.25% magnesium stearate.
  • the invention provides a novel pharmaceutical formulation comprising 0.03-0.04% 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6-dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]- 1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol triphenylacetate,. 97.7 - 99.0% lactose and 0.75 - 1 % magnesium stearate.
  • Compound (I) has been found to demonstrate sustained bronchodilation over a 24 hour period in conjunction with a favourable safety profile and thus is considered to have potential in the treatment of respiratory tract disease such as chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
  • respiratory tract disease such as chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
  • Asthma is a chronic condition, which is characterised by widespread, variable and reversible airflow obstruction. Symptoms include coughing, wheezing, breathlessness and/or a tight feeling in the chest. Asthma attacks are generally caused by exposure to a trigger, such as pollen, dust or other allergens, which causes constriction of the airways (bronchoconstriction). It will be appreciated that a subject suffering from a condition such as asthma, may variously from time to time - -
  • 'treatment' is intended to encompass prevention of such periodic attacks or exacerbations of the existing condition.
  • Such treatment may be referred to as 'maintenance treatment' or 'maintenance therapy'.
  • COPD chronic disease characterised by airways obstruction and reduced maximum expiratory flow from the lungs that manifests as persistent daily symptoms, such as shortness of breath (dyspnoea) and limitation of the ability to perform daily activities or exertion. Furthermore, there are periodic exacerbations of the condition that result in worsening of the day-to-day symptoms and activity limitation, and can also lead to hospitalisation of the patient because of the severity of the worsening symptoms/limitation. In addition, there is a progressive decline in lung function (disease progression) over several years.
  • Bronchodilator treatment in COPD includes but is not necessarily limited to reducing symptoms, particularly dyspnoea, to allow a patient to undertake more daily activities and other activities that require exertion, and preventing exacerbations.
  • Compound (I) may for example be administered by inhalation at a dose of from about 1 meg to about 400mcg/day (calculated as the free base).
  • formulations comprising Compound (I) and specifically 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6- dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol triphenylacetate with a carrier such as lactose and a ternary agent such as magnesium stearate may be administered by inhalation at a dose of Compound (I) of from about 1 mcg to 100 meg/day, for example 3, 6.25, 12.5, 25, 50 or 100 meg/day (calculated as the free base).
  • Compound (I) may be administered by inhalation at a dose of 12.5mcg/day. In another embodiment Compound (I) may be administered by inhalation at a dose of 25 meg/day. In another embodiment Compound (I) may be administered by inhalation at a dose of 50 meg/day. In general Compound (I) will be administered as a once-daily dose. - -
  • formulations of Compound (I) may be administered by means of various types of dry powder inhalers, for example, reservoir dry powder inhalers, unit-dose dry powder inhalers, pre-metered multi-dose dry powder inhalers, nasal inhalers or insufflators.
  • the formulations may be presented in unit dosage form. Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatin, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator. Each capsule or cartridge may generally contain between 1 mcg and 400 meg, e.g., between 1 mcg and I OOmcg of Compound (I).
  • Packaging of the formulation may be suitable for unit dose or multi-dose delivery.
  • a composition suitable for inhaled administration may be incorporated into a plurality of sealed dose containers provided on medicament pack(s) mounted inside a suitable inhalation device.
  • the containers may be rupturable, peelable or otherwise openable one-at-a-time and the doses of the dry powder composition administered by inhalation on a mouthpiece of the inhalation device, as known in the art.
  • the medicament pack may take a number of different forms, for instance a disk-shape or an elongate strip.
  • Representative inhalation devices are the DISKHALERTM and DISKUSTM devices, marketed by GlaxoSmithKline.
  • the DISKUSTM inhalation device is, for example, described in GB 2242134A.
  • a dry powder inhalable composition may also be provided as a bulk reservoir in an inhalation device, the device then being provided with a metering mechanism for metering a dose of the composition from the reservoir to an inhalation channel where the metered dose is able to be inhaled by a patient inhaling at a mouthpiece of the device.
  • exemplary marketed devices of this type are TURBUHALERTM of AstraZeneca, TWISTHALERTM of Schering and CLICKHALERTM of Innovata. - -
  • a further delivery method for a dry powder inhalable composition is for metered doses of the composition to be provided in capsules (one dose per capsule) which are then loaded into an inhalation device, typically by the patient on demand.
  • the device has means to rupture, pierce or otherwise open the capsule so that the dose is able to be entrained into the patient's lung when they inhale at the device mouthpiece.
  • ROTAHALERTM of GlaxoSmithKline
  • HANDIHALERTM of Boehringer Ingelheim.
  • the invention provides a formulation comprising Compound (I), a carrier, e.g. lactose and magnesium stearate in unit dose form.
  • a carrier e.g. lactose and magnesium stearate
  • Each unit dose may generally contain between 1 mcg and 400 meg, e.g., between 1 mcg and I OOmcg of Compound (I).
  • the invention provides an inhaler containing a formulation comprising Compound (I), a carrier, e.g. lactose and magnesium stearate.
  • a carrier e.g. lactose and magnesium stearate.
  • Compound (I) may be used in combination with one or more other therapeutic agents, such as inhaled corticosteroids and/or inhaled anticholinergic agents .
  • Compound (I) and said other therapeutic agent(s) may be administered separately, sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • Compound (I) and said other therapeutic agent(s) may be formulated separately and presented in separate packs or devices, or said individually formulated components may be presented in a single pack or device.
  • the individual compounds may be admixed within the same formulation, and presented as a fixed pharmaceutical combination. In general, such individual or admixed formulations of the compounds will also include pharmaceutical carriers or excipients.
  • Compound (I) may be used in combination with 6 ⁇ , 9 ⁇ -difluoro- 17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1 ,4-diene-17 ⁇ - carbothioic acid S-fluoromethyl ester (fluticasone furoate) - -
  • Compound (II) has also been the subject of extensive studies in animal models and humans and has been found to be a long acting inhaled glucocorticosteroid which has potential for once-daily administration to the lungs.
  • Compound (II) is considered to have potential in the treatment of respiratory tract disease such as chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
  • respiratory tract disease such as chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
  • Compound (II) may be presented as a formulation for inhalation, for example as described in WO02/12265.
  • Compound (II) may be presented as a dry powder formulation, optionally with a carrier or excipient, such as lactose or starch.
  • Compound (II) may be administered by inhalation at a dose of from about 25mcg to about 800mcg daily, and if necessary in divided doses.
  • the daily dose of compound (I) may be for example 25, 50, 100, 200, 300, 400, 600 or 800 meg.
  • Compound (II) will be administered as a once-daily dose. - -
  • Compound (II) may be provided in unit dose form, for example as described for Compound (I). Each unit dose of Compound (II) may contain between 25 and 800mcg.
  • the present invention provides a dry powder formulation comprising 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6-dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 - hydroxyethyl ⁇ -2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof (Compound I), a carrier such as lactose and a ternary agent such as magnesium stearate, in combination with 6 ⁇ , 9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ - hydroxy-16 ⁇ -methyl-3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (Compound II).
  • said combination may be presented in the form of a pack comprising a dry powder formulation of 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6- dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof (Compound I) in admixture with a carrier such as lactose and a ternary agent such as magnesium stearate and a separate formulation of 6 ⁇ , 9 ⁇ -difluoro-17 ⁇ -[(2-furanylcarbonyl)oxy]-11 ⁇ -hydroxy-16 ⁇ -methyl- 3-oxo-androsta-1 ,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (Compound II).
  • Said pack may comprise two separate inhaler devices, containing respectively the separate formulations of Compound (I) and Compound (II).
  • Inhaler devices for delivery of Compound (II) include those described hereinabove for delivery of Compound (I).
  • Said pack may also comprise a delivery device which permits separate containment of Compound (I) and Compound (II) optionally in admixture with one or more excipients.
  • a delivery device which permits separate containment of Compound (I) and Compound (II) optionally in admixture with one or more excipients.
  • the individual compounds of the combination are administrable simultaneously but are stored separately, e.g., in separate pharmaceutical compositions, for example as described in WO2003/061743 A1 , - -
  • a delivery device permitting separate containment of actives is an inhaler device having two medicament packs in peelable blister strip form, each pack containing pre-metered doses in blister pockets arranged along its length.
  • Said device has an internal indexing mechanism which, each time the device is actuated, peels opens a pocket of each strip and positions the packs so that each newly exposed dose of each pack is adjacent a manifold which communicates with a mouthpiece of the device.
  • each dose is simultaneously drawn out of its associated pocket into the manifold and entrained via the mouthpiece into the patient's respiratory tract.
  • the patient is administered a combination therapy consisting of a dose from each medicament pack.
  • a further device that permits separate containment of different compounds is DUOHALERTM of Innovata.
  • the present invention further provides a pharmaceutical formulation comprising a combination of Compound (I) and Compound (II) wherein at least Compound (I) is formulated with magnesium stearate.
  • the present invention provides a novel pharmaceutical product comprising
  • Compound (I) is 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6- dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2-(hydroxynnethyl)phenol triphenylacetate.
  • Compound (I) is 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6- dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol triphenylacetate.
  • each of the therapeutic agents described herein may be employed in enantiomehcally pure form, but it will be appreciated that the invention extends to mixture of isomers e.g. a racemic mixture, in relation to either or both of said therapeutic agents.
  • This invention also provides for use of a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, in the manufacture of a medicament for in treating diseases mediated via the beta-2 adrenoreceptor, for example in the treatment and/or prophylaxis of respiratory diseases.
  • a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, in the manufacture of a medicament for in treating diseases mediated via the beta-2 adrenoreceptor, for example in the treatment and/or prophylaxis of respiratory diseases.
  • the use is for the manufacture of a medicament for the treatment and/or prophylaxis of respiratory diseases. - -
  • the use is for the manufacture of a medicament for the treatment of asthma and/or chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • This invention also provides for use of a formulation comprising a Compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, in combination with a compound (II) in the manufacture of a medicament for treating diseases mediated via the beta-2 adrenoreceptor, for example in the treatment and/or prophylaxis of respiratory diseases.
  • a formulation comprising a Compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, in combination with a compound (II) in the manufacture of a medicament for treating diseases mediated via the beta-2 adrenoreceptor, for example in the treatment and/or prophylaxis of respiratory diseases.
  • the use is for the manufacture of a medicament for the treatment and/or prophylaxis of respiratory diseases, by simultaneous or sequential administration of Compound (I) and Compound (II).
  • the use is for the manufacture of a medicament for the treatment of asthma and/or chronic obstructive pulmonary disease (COPD) by simultaneous or sequential administration of Compound (I) and Compound (II).
  • COPD chronic obstructive pulmonary disease
  • the invention also provides a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, for use in the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, such as asthma and/or chronic obstructive pulmonary disease (COPD).
  • a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, for use in the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, such as asthma and/or chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the invention also provides a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, in combination with Compound (II) for use in the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, such as asthma and/or chronic obstructive pulmonary disease (COPD).
  • a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, in combination with Compound (II) for use in the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, such as asthma and/or chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Another embodiment of the invention is a method for the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, which method comprises administering to a patient in need thereof, a pharmaceutical product comprising a formulation comprising a - -
  • compound (I) a carrier such as lactose and a ternary agent such as magnesium stearate.
  • Another embodiment of the invention is a method for the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, which method comprises administering either sequentially or simultaneously, to a patient in need thereof, a pharmaceutical product comprising a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, and Compound (II).
  • the respiratory disease is selected from the group consisting of chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
  • the pharmaceutical product may be used for the treatment of respiratory disease, and more specifically the treatment of asthma and/or chronic obstructive pulmonary disease (COPD), by simultaneous or successive administration of Compound (I) and Compound (II).
  • COPD chronic obstructive pulmonary disease
  • 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6-dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2- (hydroxymethyl)phenol, and its salts, including 4- ⁇ (1 R)-2-[(6- ⁇ 2-[(2,6- dichlorobenzyl)oxy]ethoxy ⁇ hexyl)amino]-1 -hydroxyethyl ⁇ -2-(hydroxymethyl)phenol triphenylacetate may be prepared as described in WO 2003/024439.
  • Compound (II) has been studied in a number of clinical pharmacology studies, including single- and repeat-dose studies and at a range of doses. In addition, these studies have evaluated Compound (II) with the excipients cellobiose octaacetate and magnesium stearate.
  • Lactose monohydrate complying with the requirements of Ph.Eur/USNF was used. Before use, the Lactose Monohydrate was sieved through a coarse screen (mesh size 800 microns) to deaggregate the material. Compound (I) triphenylacetate was micronised before use in an APTM microniser to give a MMD (mass median diameter) of from 2 to 5 microns.
  • the magnesium stearate (typically 13Og) was combined with lactose monohydrate and blended using either a high shear mixer (a QMM, PMA or TRV series mixer) or a low shear tumbling blender (a Turbula mixer) to provide a magnesium stearate/lactose premix, hereinafter referred to as blend A.
  • a high shear mixer a QMM, PMA or TRV series mixer
  • a Turbula mixer a low shear tumbling blender
  • Final blend B was obtained by first pre-mixing an appropriate quantity of blend A with compound (I) triphenylacetate (typically 5-165g) using either a high shear mixer (a QMM, PMA or TRV series mixer) or a low shear tumbling blender (a Turbula mixer) and then blending that blend A/compound (I) triphenylacetate premix with further blend A in a weight ratio appropriate to provide blend B containing the magnesium stearate in the required quantity.
  • Compound (I) triphenylacetate was combined with lactose monohydrate and blended using a high shear TRV series mixer.
  • the final concentration of compound (I) triphenylacetate in the blends was typically in the range 0.02 % w/w - 0.8% w/w free base equivalent. - -
  • the blended composition was transferred into blister strips (typical nominal mean quantity of blend B per blister is 12.5-13.5mg) of the type generally used for the supply of dry powder for inhalation and the blister strips were sealed in the customary fashion.
  • the quantity of compound (I) triphenylacetate used is based on a base to salt conversion factor of 1.59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.

Description

PHARMACEUTICAL FORMULATIONS COMPRISING
4- { (1 R) -2- [ ( 6- { 2- [ (2,6-DICHLOROBENZYL) OXY] ETHOXY}HEXYL) AMINO] -1-HYDROXYETHYL} -2- (HYDROXYM ETHYL) PHENOL
FIELD OF THE INVENTION
This invention relates to pharmaceutical products and compositions for use in treating diseases mediated via the beta-2 adrenoreceptor, for example in the treatment and/or prophylaxis of respiratory diseases. More particularly this invention relates to novel compositions of the compound 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol and pharmaceutically acceptable salts thereof and combinations thereof with other therapeutic agents, in particular 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11 β- hydroxy-16α-methyl-3-oxo-androsta-1 ,4-diene-17β-carbothioic acid S-fluoromethyl ester (fluticasone furoate), and the use of said compositions and combinations in medicine, particularly in the treatment of asthma and related disorders, such as the treatment of chronic obstructive pulmonary disease (COPD).
BACKGROUND OF THE INVENTION Selective beta-2 adrenoreceptor agonists have been used in the prophylaxis and treatment of clinical conditions for which a bronchodilating agent has been indicated. Such conditions include diseases associated with airflow obstruction such as asthma, chronic obstructive pulmonary diseases (COPD) (e.g. chronic and wheezy bronchitis, emphysema), respiratory tract infection and upper respiratory tract disease (e.g. rhinitis, including seasonal and allergic rhinitis).
In particular, asthma and other related disorders are typically treated with beta-2 adrenergic receptor agonists (beta-2 agonists) as they provide a bronchodilator effect to the patient, resulting in relief from the symptoms of breathlessness. Within the beta-2 agonist class there are presently available short acting compounds for immediate relief, such as salbutamol, biltolterol, pirbuterol and terbutaline. There are also longer acting compounds commercially available, such as salmeterol and formoterol. Although salmeterol and formoterol are effective bronchodilators, in general their duration of action in human subjects is around 12 hours, hence twice daily dosing is generally required.
While the beta-2 agonists provide for symptomatic relief of bronchoconstriction in patients, another component of asthma, i.e. inflammation, often requires separate treatment. Typically, this treatment has been with a steroid. Currently available corticosteroids for use include beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, mometasone furoate and triamcinolone.
WO 03/024439 describes compounds of the general formula:
Figure imgf000003_0001
and salts, solvates, and physiologically functional derivatives thereof.
The compound 4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 - hydroxyethyl}-2-(hydroxymethyl)phenol is specifically described in WO03/024439, as are pharmaceutically acceptable salts thereof, in particular the acetate, thphenylacetate, α-phenylcinnamate, 1 -naphthoate and (R)-mandelate salts.
WO02/12265 discloses the compound 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]- 11 β-hydroxy-16α-methyl-3-oxo-androsta-1 ,4-diene-17β-carbothioic acid S- fluoromethyl ester. SUMMARY OF THE INVENTION
In a first aspect the present invention provides a novel pharmaceutical formulation comprising a dry powder formulation of 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol:
Figure imgf000004_0001
Compound (I) or a pharmaceutically acceptable salt thereof in admixture with a carrier such as lactose and a ternary agent such as magnesium stearate.
Hereinafter, Compound (I) may refer to the free base depicted above, and/or one or more salts thereof, as dictated by the context.
It will be appreciated that Compound (I) may exist in enantiomerically pure form or as a mixture of isomers, e.g. a racemic mixture.
In one embodiment Compound (I) is 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate.
In another embodiment Compound (I) is 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol α- phenylcinnamate.
In another embodiment the present invention provides a pharmaceutical product comprising: - -
a) a pharmaceutical formulation comprising 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof (Compound I), a carrier such as lactose and a ternary agent such as magnesium stearate; and b) 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11 β-hydroxy-16α-methyl-3-oxo- androsta-1 ,4-diene-17β-carbothioic acid S-fluoromethyl ester
Figure imgf000005_0001
Compound (II)
This invention also provides for use of said pharmaceutical formulation and/or said pharmaceutical product in the manufacture of a medicament for the treatment and/or prophylaxis of respiratory diseases.
In one embodiment the use is for the manufacture of a medicament for the treatment of asthma and/or chronic obstructive pulmonary disease (COPD).
The invention also provides said pharmaceutical formulation and/or said pharmaceutical product for use in the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, such as asthma and/or chronic obstructive pulmonary disease (COPD).
Another embodiment of the invention is a method for the treatment and/or prophylaxis of respiratory diseases, comprising administering to a patient in need thereof said - -
pharmaceutical formulation or said pharmaceutical product comprising Compound (I) and Compound (II) wherein Compound (I) and Compound (II) are administered either sequentially or simultaneously.
In one embodiment of the invention the respiratory disease is selected from the group consisting of chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to a pharmaceutical product comprising:
4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-
(hydroxymethyl)phenol:
Figure imgf000006_0001
Compound (I) or a pharmaceutically acceptable salt thereof.
To date, 4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 - hydroxyethyl}-2-(hydroxymethyl)phenol (and salts thereof) has been extensively tested in animal and human studies and has been found to demonstrate sustained bronchodilation over a 24 hour period in conjunction with a favourable safety profile and thus has the potential for once-daily administration.
In a first aspect the present invention provides a novel formulation comprising 4- {(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2- (hydroxymethyl)phenol: - -
Figure imgf000007_0001
or a pharmaceutically acceptable salt thereof (Compound I), a carrier such as lactose and a ternary agent such as magnesium stearate.
Said formulation is suitable for topical delivery to the lung by inhalation, and may be administered by inhalation via the nose or mouth.
Formulations of Compound (I) with lactose and magnesium stearate have been found to demonstrate good levels of physical and chemical stability of the product, including at lower product strengths.
Said formulation may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the active ingredient into association with said carrier and ternary agent. Thus the formulations may be prepared by uniformly and intimately bringing into association Compound (I) with lactose and magnesium stearate. The formulation may be if desired filled into suitable unit dose forms.
Compound (I) is generally present in an amount of 0.020 - 3.0%, e.g. 0.024-0.8% by weight of the formulation wherein the weight of Compound (I) is calculated as the free base.
Medicaments for administration by inhalation desirably have a controlled particle size. The optimum particle size for inhalation into the bronchial system is usually 1 -1 Oμm, preferably 2-5μm. Particles having a size above 20μm are generally too large when inhaled to reach the small airways. To achieve these particle sizes the particles of the active ingredient as produced may be size reduced by conventional means e.g. by micron ization. The desired fraction may be separated out by air classification or sieving. Preferably, the particles will be crystalline.
The carrier, e.g. lactose generally forms from 94 -99%, e.g. 97.7 - 99.0% by weight of the formulation.
In general, the particle size of the carrier, for example lactose, will be much greater than the inhaled medicament within the present invention. When the carrier is lactose it will typically be present as milled lactose, wherein not more than 85% of lactose particles will have a MMD (mass median diameter) of 60-90μm and not more than 15% will have a MMD of less than 15μm.
In one embodiment the lactose is anhydrous lactose or lactose monohydrate.
Magnesium stearate is generally present in an amount of 0.2 to 2%, e.g. 0.6 to 2%%, e.g. 0.75%, 1 %, 1.25% or 1.5%.
The magnesium stearate will typically have a particle size in the range 1 to 50μm, and more particularly 1 - 20μm, e.g.1 -10μm. As is well known in the art stearic acid may comprise a mixture of stearic and palmitic acids; small amounts of other acids, e.g., lauric acid, myristic acid and/or arachic acid may also be present. Hence magnesium stearate similarly may comprise a mixture of salts formed with said acids. In general, the proportion of stearic acid present is 40.0 to 100%. Typically the proportion of stearic acid is present in an amount from 60 to 75% with the total proportion of stearic and palmitic acids in an amount from 90-100% e.g. 96-100%.
In one embodiment the aforesaid formulations comprise Compound (I), lactose and magnesium stearate.
In one embodiment the aforesaid formulations consist of Compound (I), lactose and magnesium stearate. - -
Pharmaceutically acceptable acid addition salts of Compound (I) include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, thfluoroacetic, triphenylacetic, phenylacetic, substituted phenyl acetic e.g., methoxyphenyl acetic, sulphamic, sulphanilic, succinic, oxalic, fumaric, maleic, malic, glutamic, aspartic, oxaloacetic, methanesulphonic, ethanesulphonic, arylsulphonic (for example p-toluenesulphonic, benzenesulphonic, naphthalenesulphonic or naphthalenedisulphonic), salicylic, glutahc, gluconic, tricarballylic, mandelic, cinnamic, substituted cinnamic (for example, methyl, methoxy, halo or phenyl substituted cinnamic, including 4-methyl and 4-methoxycinnamic acid and α-phenyl cinnamic acid), ascorbic, oleic, naphthoic, hydroxynaphthoic (for example 1 - or 3-hydroxy-2-naphthoic), naphthaleneacrylic (for example naphthalene- 2-acrylic), benzoic, 4-methoxybenzoic, 2- or 4-hydroxybenzoic, 4-chlorobenzoic, 4-phenylbenzoic, benzeneacrylic (for example 1 ,4-benzenediacrylic) and isethionic acids.
In one embodiment the pharmaceutically acceptable salt of Compound (I) is selected from the acetate, 1 -naphthoate and (R)-mandelate salts.
In another embodiment the pharmaceutically acceptable salt of Compound (I) is the α-phenylcinnamate salt.
In another embodiment the pharmaceutically acceptable salt of Compound (I) is the triphenylacetate salt.
In one embodiment the invention provides a novel pharmaceutical formulation comprising 4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 - hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate, lactose and magnesium stearate. In a further embodiment the invention provides a novel pharmaceutical formulation consisting of 4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 - hydroxyethyl}-2-(hydroxymethyl)phenol thphenylacetate, lactose and magnesium stearate.
In said formulations the specified components are generally present in the amounts specified hereinabove.
In one embodiment the invention provides a novel pharmaceutical formulation comprising 0.03-0.04% 4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]- 1 -hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate, 94 -99%, lactose and 0.75 - 1.25% magnesium stearate.
In one embodiment the invention provides a novel pharmaceutical formulation comprising 0.03-0.04% 4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]- 1 -hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate,. 97.7 - 99.0% lactose and 0.75 - 1 % magnesium stearate.
As noted hereinabove, Compound (I) has been found to demonstrate sustained bronchodilation over a 24 hour period in conjunction with a favourable safety profile and thus is considered to have potential in the treatment of respiratory tract disease such as chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
Asthma is a chronic condition, which is characterised by widespread, variable and reversible airflow obstruction. Symptoms include coughing, wheezing, breathlessness and/or a tight feeling in the chest. Asthma attacks are generally caused by exposure to a trigger, such as pollen, dust or other allergens, which causes constriction of the airways (bronchoconstriction). It will be appreciated that a subject suffering from a condition such as asthma, may variously from time to time - -
display no overt symptoms of the conditions, or may suffer from periodic attacks during which symptoms are displayed or may experience exacerbations or worsening of the condition. In this context the term 'treatment' is intended to encompass prevention of such periodic attacks or exacerbations of the existing condition. Such treatment may be referred to as 'maintenance treatment' or 'maintenance therapy'.
COPD is a chronic disease characterised by airways obstruction and reduced maximum expiratory flow from the lungs that manifests as persistent daily symptoms, such as shortness of breath (dyspnoea) and limitation of the ability to perform daily activities or exertion. Furthermore, there are periodic exacerbations of the condition that result in worsening of the day-to-day symptoms and activity limitation, and can also lead to hospitalisation of the patient because of the severity of the worsening symptoms/limitation. In addition, there is a progressive decline in lung function (disease progression) over several years.
Bronchodilator treatment in COPD includes but is not necessarily limited to reducing symptoms, particularly dyspnoea, to allow a patient to undertake more daily activities and other activities that require exertion, and preventing exacerbations.
Compound (I) may for example be administered by inhalation at a dose of from about 1 meg to about 400mcg/day (calculated as the free base). In one embodiment, formulations comprising Compound (I) and specifically 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate with a carrier such as lactose and a ternary agent such as magnesium stearate may be administered by inhalation at a dose of Compound (I) of from about 1 mcg to 100 meg/day, for example 3, 6.25, 12.5, 25, 50 or 100 meg/day (calculated as the free base). In one embodiment, Compound (I) may be administered by inhalation at a dose of 12.5mcg/day. In another embodiment Compound (I) may be administered by inhalation at a dose of 25 meg/day. In another embodiment Compound (I) may be administered by inhalation at a dose of 50 meg/day. In general Compound (I) will be administered as a once-daily dose. - -
In one embodiment of this invention formulations of Compound (I) may be administered by means of various types of dry powder inhalers, for example, reservoir dry powder inhalers, unit-dose dry powder inhalers, pre-metered multi-dose dry powder inhalers, nasal inhalers or insufflators.
The formulations may be presented in unit dosage form. Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatin, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator. Each capsule or cartridge may generally contain between 1 mcg and 400 meg, e.g., between 1 mcg and I OOmcg of Compound (I).
Packaging of the formulation may be suitable for unit dose or multi-dose delivery. In one embodiment, a composition suitable for inhaled administration may be incorporated into a plurality of sealed dose containers provided on medicament pack(s) mounted inside a suitable inhalation device. The containers may be rupturable, peelable or otherwise openable one-at-a-time and the doses of the dry powder composition administered by inhalation on a mouthpiece of the inhalation device, as known in the art. The medicament pack may take a number of different forms, for instance a disk-shape or an elongate strip. Representative inhalation devices are the DISKHALER™ and DISKUS™ devices, marketed by GlaxoSmithKline. The DISKUS™ inhalation device is, for example, described in GB 2242134A.
A dry powder inhalable composition, may also be provided as a bulk reservoir in an inhalation device, the device then being provided with a metering mechanism for metering a dose of the composition from the reservoir to an inhalation channel where the metered dose is able to be inhaled by a patient inhaling at a mouthpiece of the device. Exemplary marketed devices of this type are TURBUHALER™ of AstraZeneca, TWISTHALER™ of Schering and CLICKHALER™ of Innovata. - -
A further delivery method for a dry powder inhalable composition is for metered doses of the composition to be provided in capsules (one dose per capsule) which are then loaded into an inhalation device, typically by the patient on demand. The device has means to rupture, pierce or otherwise open the capsule so that the dose is able to be entrained into the patient's lung when they inhale at the device mouthpiece. As marketed examples of such devices there may be mentioned ROTAHALER™ of GlaxoSmithKline and HANDIHALER™ of Boehringer Ingelheim.
In a further embodiment the invention provides a formulation comprising Compound (I), a carrier, e.g. lactose and magnesium stearate in unit dose form. Each unit dose may generally contain between 1 mcg and 400 meg, e.g., between 1 mcg and I OOmcg of Compound (I).
In a further embodiment the invention provides an inhaler containing a formulation comprising Compound (I), a carrier, e.g. lactose and magnesium stearate.
Compound (I) may be used in combination with one or more other therapeutic agents, such as inhaled corticosteroids and/or inhaled anticholinergic agents . Compound (I) and said other therapeutic agent(s) may be administered separately, sequentially or simultaneously in separate or combined pharmaceutical formulations. Thus Compound (I) and said other therapeutic agent(s) may be formulated separately and presented in separate packs or devices, or said individually formulated components may be presented in a single pack or device. Where appropriate, the individual compounds may be admixed within the same formulation, and presented as a fixed pharmaceutical combination. In general, such individual or admixed formulations of the compounds will also include pharmaceutical carriers or excipients.
In one embodiment Compound (I) may be used in combination with 6α, 9α-difluoro- 17α-[(2-furanylcarbonyl)oxy]-11 β-hydroxy-16α-methyl-3-oxo-androsta-1 ,4-diene-17β- carbothioic acid S-fluoromethyl ester (fluticasone furoate) - -
Figure imgf000014_0001
(Compound II).
Compound (II) has also been the subject of extensive studies in animal models and humans and has been found to be a long acting inhaled glucocorticosteroid which has potential for once-daily administration to the lungs.
Compound (II) is considered to have potential in the treatment of respiratory tract disease such as chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
Compound (II) may be presented as a formulation for inhalation, for example as described in WO02/12265. Thus for example Compound (II) may be presented as a dry powder formulation, optionally with a carrier or excipient, such as lactose or starch.
For use according to the present invention, Compound (II) may be administered by inhalation at a dose of from about 25mcg to about 800mcg daily, and if necessary in divided doses. Thus, the daily dose of compound (I) may be for example 25, 50, 100, 200, 300, 400, 600 or 800 meg. In general Compound (II) will be administered as a once-daily dose. - -
Compound (II) may be provided in unit dose form, for example as described for Compound (I). Each unit dose of Compound (II) may contain between 25 and 800mcg.
In a further aspect the present invention provides a dry powder formulation comprising 4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 - hydroxyethyl}-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof (Compound I), a carrier such as lactose and a ternary agent such as magnesium stearate, in combination with 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11 β- hydroxy-16α-methyl-3-oxo-androsta-1 ,4-diene-17β-carbothioic acid S-fluoromethyl ester (Compound II).
In one embodiment said combination may be presented in the form of a pack comprising a dry powder formulation of 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof (Compound I) in admixture with a carrier such as lactose and a ternary agent such as magnesium stearate and a separate formulation of 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11 β-hydroxy-16α-methyl- 3-oxo-androsta-1 ,4-diene-17β-carbothioic acid S-fluoromethyl ester (Compound II).
Said pack may comprise two separate inhaler devices, containing respectively the separate formulations of Compound (I) and Compound (II). Inhaler devices for delivery of Compound (II) include those described hereinabove for delivery of Compound (I).
Said pack may also comprise a delivery device which permits separate containment of Compound (I) and Compound (II) optionally in admixture with one or more excipients. Thus, for example, the individual compounds of the combination are administrable simultaneously but are stored separately, e.g., in separate pharmaceutical compositions, for example as described in WO2003/061743 A1 , - -
WO2007/012871 A1 and/or WO2007/068896. In one embodiment a delivery device permitting separate containment of actives is an inhaler device having two medicament packs in peelable blister strip form, each pack containing pre-metered doses in blister pockets arranged along its length. Said device has an internal indexing mechanism which, each time the device is actuated, peels opens a pocket of each strip and positions the packs so that each newly exposed dose of each pack is adjacent a manifold which communicates with a mouthpiece of the device. When the patient inhales at the mouthpiece, each dose is simultaneously drawn out of its associated pocket into the manifold and entrained via the mouthpiece into the patient's respiratory tract. Thus, each time the device is used, the patient is administered a combination therapy consisting of a dose from each medicament pack.
A further device that permits separate containment of different compounds is DUOHALER™ of Innovata.
The present invention further provides a pharmaceutical formulation comprising a combination of Compound (I) and Compound (II) wherein at least Compound (I) is formulated with magnesium stearate.
In a further aspect the present invention provides a novel pharmaceutical product comprising
(a) a dry powder formulation of 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof (Compound I) in admixture with a carrier such as lactose and a ternary agent such as magnesium stearate, and
(b) a dry powder formulation of 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11 β- hydroxy-16α-methyl-3-oxo-androsta-1 ,4-diene-17β-carbothioic acid S-fluoromethyl ester (Compound II). - -
In one embodiment on the invention, Compound (I) is 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxynnethyl)phenol triphenylacetate.
In a yet further aspect there is provided a delivery device containing as separate formulations:
(a) a dry powder formulation comprising 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt thereof (Compound I), a carrier such as lactose and a ternary agent such as magnesium stearate, and
(b) a dry powder formulation comprising 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]- 11 β-hydroxy-16α-methyl-3-oxo-androsta-1 ,4-diene-17β-carbothioic acid S- fluoromethyl ester (Compound II).
In one embodiment of this invention, Compound (I) is 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate.
In general each of the therapeutic agents described herein may be employed in enantiomehcally pure form, but it will be appreciated that the invention extends to mixture of isomers e.g. a racemic mixture, in relation to either or both of said therapeutic agents.
This invention also provides for use of a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, in the manufacture of a medicament for in treating diseases mediated via the beta-2 adrenoreceptor, for example in the treatment and/or prophylaxis of respiratory diseases.
In one embodiment the use is for the manufacture of a medicament for the treatment and/or prophylaxis of respiratory diseases. - -
In another embodiment the use is for the manufacture of a medicament for the treatment of asthma and/or chronic obstructive pulmonary disease (COPD).
This invention also provides for use of a formulation comprising a Compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, in combination with a compound (II) in the manufacture of a medicament for treating diseases mediated via the beta-2 adrenoreceptor, for example in the treatment and/or prophylaxis of respiratory diseases.
In one embodiment the use is for the manufacture of a medicament for the treatment and/or prophylaxis of respiratory diseases, by simultaneous or sequential administration of Compound (I) and Compound (II).
In another embodiment the use is for the manufacture of a medicament for the treatment of asthma and/or chronic obstructive pulmonary disease (COPD) by simultaneous or sequential administration of Compound (I) and Compound (II).
The invention also provides a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, for use in the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, such as asthma and/or chronic obstructive pulmonary disease (COPD).
The invention also provides a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, in combination with Compound (II) for use in the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, such as asthma and/or chronic obstructive pulmonary disease (COPD).
Another embodiment of the invention is a method for the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, which method comprises administering to a patient in need thereof, a pharmaceutical product comprising a formulation comprising a - -
compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate.
Another embodiment of the invention is a method for the treatment and/or prophylaxis of inflammatory or respiratory tract diseases, which method comprises administering either sequentially or simultaneously, to a patient in need thereof, a pharmaceutical product comprising a formulation comprising a compound (I), a carrier such as lactose and a ternary agent such as magnesium stearate, and Compound (II).
In one embodiment of the invention the respiratory disease is selected from the group consisting of chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
In another embodiment of the invention the pharmaceutical product may be used for the treatment of respiratory disease, and more specifically the treatment of asthma and/or chronic obstructive pulmonary disease (COPD), by simultaneous or successive administration of Compound (I) and Compound (II).
6α, 9α-Difluoro-17α-[(2-furanylcarbonyl)oxy]-11 β-hydroxy-16α-methyl-3-oxo-androsta- 1 ,4-diene-17β-carbothioic acid S-fluoromethyl ester may be prepared as described in WO 2002/12265.
4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2- (hydroxymethyl)phenol, and its salts, including 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate may be prepared as described in WO 2003/024439.
Clinical studies of Compound (I) and Compound (II)
Compound (I) as the α-phenylcinnamate salt and the triphenylacetate salt has been studied in a number of clinical pharmacology studies, including single- and repeat- - -
dose studies. In addition, these studies have evaluated Compound (I) with the excipients cellobiose octaacetate and magnesium stearate.
In asthmatic patients, a statistically and clinically significant improvement in trough (24-hour) FEV1 was observed for all doses of Compound (I) compared to placebo. Single doses of 25 meg to 100 meg of Compound (I) thphenylacetate (containing lactose and magnesium stearate) demonstrated 24 hour duration of action as assessed by a 20OmL or greater increase in mean 23 to 24 hour post-dose FEV1 versus placebo. In one study in asthmatic patients 100 meg of Compound (I) triphenylacetate formulated with lactose and magnesium stearate has shown a favourable onset of action.
In COPD patients, treatment with I OOmcg and 400mcg Compound (I) alpha- phenylcinnamate (with lactose alone) achieved a clinically relevant adjusted mean difference from placebo in weighted mean trough FEV1 (22 to 24 hrs) of >100ml_. Single doses of 25 meg to 100 meg of Compound (I) triphenylacetate (containing lactose and magnesium stearate) demonstrated 24 hour duration of action as assessed by a 19OmL or greater increase in mean 23 to 24 hour post-dose FEV1 versus placebo).
Compound (II) has been studied in a number of clinical pharmacology studies, including single- and repeat-dose studies and at a range of doses. In addition, these studies have evaluated Compound (II) with the excipients cellobiose octaacetate and magnesium stearate.
In asthmatic patients, a statistically and clinically significant improvement in trough (24-hour) FEV1 was observed at doses of from 100 to 400 meg Compound (II) compared to placebo.
A study has also been carried out to evaluate the pharmacodynamics and pharmacokinetics of Compound (I) and Compound (II) when administered separately and in combination as a single dose from a novel dry powder device in healthy subjects.
Pharmaceutical Formulations Preparation of blends
Pharmaceutical grade lactose monohydrate complying with the requirements of Ph.Eur/USNF was used. Before use, the Lactose Monohydrate was sieved through a coarse screen (mesh size 800 microns) to deaggregate the material. Compound (I) triphenylacetate was micronised before use in an APTM microniser to give a MMD (mass median diameter) of from 2 to 5 microns.
Pharmaceutical grade magnesium stearate, complying with the requirements of Ph.Eur/NF was used as supplied with a mass median particle size < 10 microns.
The magnesium stearate (typically 13Og) was combined with lactose monohydrate and blended using either a high shear mixer (a QMM, PMA or TRV series mixer) or a low shear tumbling blender (a Turbula mixer) to provide a magnesium stearate/lactose premix, hereinafter referred to as blend A.
Final blend B was obtained by first pre-mixing an appropriate quantity of blend A with compound (I) triphenylacetate (typically 5-165g) using either a high shear mixer (a QMM, PMA or TRV series mixer) or a low shear tumbling blender (a Turbula mixer) and then blending that blend A/compound (I) triphenylacetate premix with further blend A in a weight ratio appropriate to provide blend B containing the magnesium stearate in the required quantity. Compound (I) triphenylacetate was combined with lactose monohydrate and blended using a high shear TRV series mixer. The final concentration of compound (I) triphenylacetate in the blends was typically in the range 0.02 % w/w - 0.8% w/w free base equivalent. - -
The blended composition was transferred into blister strips (typical nominal mean quantity of blend B per blister is 12.5-13.5mg) of the type generally used for the supply of dry powder for inhalation and the blister strips were sealed in the customary fashion.
Using the above-described procedure the following exemplary formulations were prepared:
Figure imgf000022_0001
1. The quantity of compound (I) triphenylacetate used is based on a base to salt conversion factor of 1.59

Claims

Claims
1. A pharmaceutical formulation comprising 4-{(1 R)-2-[(6-{2-[(2,6- dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 -hydroxyethyl}-2-(hydroxymethyl)phenol:
Figure imgf000023_0001
Compound (I) or a pharmaceutically acceptable salt thereof, a carrier and a ternary agent.
2. A pharmaceutical formulation according to Claim 1 wherein the carrier is lactose.
3. A pharmaceutical formulation according to Claim 1 or Claim 2 wherein the ternary agent is magnesium stearate.
4. A pharmaceutical formulation according to any of Claims 1 to 3 wherein Compound (I) is 4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 - hydroxyethyl}-2-(hydroxymethyl)phenol thphenylacetate.
5. A pharmaceutical formulation according to any of Claims 1 to 3 wherein Compound (I) is 4-{(1 R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1 - hydroxyethyl}-2-(hydroxymethyl)phenol α-phenylcinnamate.
6. A pharmaceutical formulation according to any of Claims 1 to 5 in a form suitable for administration by oral or nasal inhalation.
7. A pharmaceutical formulation as claimed in any one of Claims 1 to 6 wherein Compound (I) is present in an amount of 1 to 400 meg/dose.
8. Use of a pharmaceutical formulation according to any of Claims 1 to 7 in the manufacture of a medicament for the treatment of respiratory disease.
9. The use according to Claim 8, for the manufacture of a medicament for the treatment of asthma.
10. The use according to Claim 9 for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease (COPD).
11. A method for the treatment of respiratory disease, comprising administering to a patient in need thereof, a pharmaceutical formulation according to any of Claims 1 to 7.
12. A method according to Claim 11 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
13. A method according to Claim 11 or Claim 12 wherein administration is via inhalation by the mouth or nose.
14. A method according to any of Claims 11 to 13 wherein the product is administered once per day.
15. A pharmaceutical product comprising a) a pharmaceutical formulation according to any of Claims 1 to 7; and b) 6α, 9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11 β-hydroxy-16α-methyl-3-oxo- androsta-1 ,4-diene-17β-carbothioic acid S-fluoromethyl ester: - -
Figure imgf000025_0001
Compound (II).
16. A product according to Claim 15 wherein Compound (I) and Compound (II) are presented in a form adapted for separate administration.
17. A product according to Claim 15 wherein Compound (I) and Compound (II) are presented in a form adapted for sequential administration.
18. A product according to Claim 15 wherein Compound (I) and Compound (II) are presented in a form adapted for simultaneous administration.
19. A product according to any of claims 15 to 18 wherein Compound (I) and Compound (II) are presented as separate compositions.
20. A product according to Claim 18 wherein Compound (I) and Compound (II) are in admixture with each other.
21. A product as claimed in any of claims 15 to 20 wherein Compound (II) is presented in the form of a dry powder composition.
22. A product according to any of Claims 15 to 21 wherein Compound (II) is formulated with a pharmaceutically acceptable carrier or excipient. - -
23. A product according to any of Claims 15 to 22 in a form suitable for administration by oral or nasal inhalation.
24. A product as claimed in any one of Claims 15 to 23 wherein Compound (II) is present in an amount of about 25mcg to about 800mcg/dose.
25. Use of a product according to any of Claims 15 to 24 in the manufacture of a medicament for the treatment of respiratory disease.
26. The use according to Claim 25, for the manufacture of a medicament for the treatment of asthma.
27. The use according to Claim 25, for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease (COPD).
28. A method for the treatment of respiratory disease, comprising administering to a patient in need thereof, a pharmaceutical product according to any of Claims 15 to 24.
29. A method according to Claim 28 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
30. A method according to Claim 28 or Claim 29 wherein administration is via inhalation by the mouth or nose.
31. A method according to any of Claims 28 to 30 wherein Compound (I) and Compound (II) are administered simultaneously.
32. A method according to any of Claims 28 to 31 wherein the product is administered once per day.
PCT/EP2009/052306 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol WO2010097115A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
EP19175120.5A EP3578169B1 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
PCT/EP2009/052306 WO2010097115A1 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol
DK19175120.5T DK3578169T3 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
ES09779096T ES2739352T3 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4 - {(1R) -2 - [(6- {2 - [(2,6-dichlorobenzyl) oxy] ethoxy} hexyl) amino] -1-hydroxyethyl} -2- (hydroxymethyl) phenol
HUE19175120A HUE067290T2 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
ES19175120T ES2994042T3 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
PL09779096T PL2400950T3 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
PL19175120.5T PL3578169T3 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
US13/148,982 US11116721B2 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
EP09779096.8A EP2400950B1 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
PT09779096T PT2400950T (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
LTEP19175120.5T LT3578169T (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
FIEP19175120.5T FI3578169T3 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
SI200932199T SI3578169T1 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-((1 r)-2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol
EP24179210.0A EP4403231A3 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
SI200931991T SI2400950T1 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-((1 r)-2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol
HRP20241000TT HRP20241000T3 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
HUE09779096A HUE045917T2 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
JP2011551415A JP5809985B2 (en) 2009-02-26 2009-02-26 A medicament comprising 4-{(1R) -2-[(6- {2-[(2,6-dichlorobenzyl) oxy] ethoxy} hexyl) amino] -1-hydroxyethyl} -2- (hydroxymethyl) phenol Formulation
DK09779096.8T DK2400950T3 (en) 2009-02-26 2009-02-26 PHARMACEUTICAL FORMULA comprising 4 - {(1 R) -2 - [(6- {2 - [(2,6-DICHLORBENZYL) OXY] ETHOXY} HEXYL) AMINO] -1-HYDROXYETHYL} -2- (HYDROXYMETHYL) PHENOL
PT191751205T PT3578169T (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
LTEP09779096.8T LT2400950T (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
HRP20191257TT HRP20191257T1 (en) 2009-02-26 2019-07-12 Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol
CY20191100870T CY1121914T1 (en) 2009-02-26 2019-08-13 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-{(lR)-2-[(6-{2-[2,6-DICHLOROBENZYL)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-methyl)phenol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/052306 WO2010097115A1 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP19175120.5A Previously-Filed-Application EP3578169B1 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol

Publications (1)

Publication Number Publication Date
WO2010097115A1 true WO2010097115A1 (en) 2010-09-02

Family

ID=40547825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/052306 WO2010097115A1 (en) 2009-02-26 2009-02-26 Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol

Country Status (14)

Country Link
US (1) US11116721B2 (en)
EP (3) EP3578169B1 (en)
JP (1) JP5809985B2 (en)
CY (1) CY1121914T1 (en)
DK (2) DK2400950T3 (en)
ES (2) ES2994042T3 (en)
FI (1) FI3578169T3 (en)
HR (2) HRP20241000T3 (en)
HU (2) HUE045917T2 (en)
LT (2) LT3578169T (en)
PL (2) PL3578169T3 (en)
PT (2) PT3578169T (en)
SI (2) SI3578169T1 (en)
WO (1) WO2010097115A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011067212A1 (en) * 2009-12-01 2011-06-09 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2012028663A1 (en) * 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JP2014516062A (en) * 2011-06-08 2014-07-07 グラクソ グループ リミテッド Combinations containing umecridinium and corticosteroids
WO2014155134A1 (en) 2013-03-28 2014-10-02 Vectura Limited Use of stearate in an inhalable formulation
EP2957553A1 (en) * 2014-06-16 2015-12-23 Arven Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations of vilanterol
EP2957552A1 (en) * 2014-06-16 2015-12-23 Arven Ilac Sanayi Ve Ticaret A.S. Vilanterol formulations
EP2957551A1 (en) * 2014-06-16 2015-12-23 Arven Ilac Sanayi Ve Ticaret A.S. Dry powder formulations comprising vilanterol
EP2957550A1 (en) * 2014-06-16 2015-12-23 Arven Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations comprising vilanterol
WO2016005434A1 (en) * 2014-07-09 2016-01-14 Arven Ilac Sanayi Ve Ticaret A.S. Novel process for the preparation of dry powder formulations
WO2016005440A1 (en) * 2014-07-09 2016-01-14 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of dry powder formulations
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US20170266135A1 (en) * 2014-07-09 2017-09-21 Arven Ilac Sanayi Ve Ticaret A.S. Process for preparing the inhalation formulations
US9795561B2 (en) 2012-12-17 2017-10-24 Glaxo Group Limited Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022146257A1 (en) * 2020-12-31 2022-07-07 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239932A1 (en) * 2003-07-11 2006-10-26 Monteith Michael J Pharmaceutical formulations comprising magnesium stearate

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB124009A (en) 1918-01-12 1919-03-12 Walter Edward Kimber Improvements in and connected with the Manufacture of Tools for Turning, Planing, Boring and similar purposes.
GB124010A (en) 1919-01-10 1919-03-20 Rene Emile Dior Improved Process for the Manufacture of Synthetic Resins.
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB1424432A (en) 1972-03-25 1976-02-11 Degussa Pharmaceutical compositions
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
ATE23272T1 (en) 1981-07-08 1986-11-15 Draco Ab POWDER INHALER.
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
NZ205892A (en) 1982-10-08 1987-07-31 Glaxo Group Ltd Inhalation device; including a penetrating member and rotatable indexing means
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
PT83094B (en) 1985-07-30 1993-07-30 Glaxo Group Ltd DEVICES PROPER FOR THE ADMINISTRATION OF MEDICINES TO PATIENTS
GB8530365D0 (en) 1985-12-10 1986-01-22 Univ Bath Manufacture of moulded products
IT1204826B (en) 1986-03-04 1989-03-10 Chiesi Farma Spa INHALATION PHARMACEUTICAL COMPOSITIONS
CA1329526C (en) 1987-08-20 1994-05-17 Hiroshi Ikura Powdery medicine applicator device
US4994276A (en) 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
GB8820353D0 (en) 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
TW197380B (en) 1990-03-02 1993-01-01 Glaxo Group Ltd
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280968B6 (en) 1990-03-02 2000-10-09 Glaxo Group Limited Medicament pack for use in an inhalation device
FR2660634B1 (en) 1990-04-06 1992-10-16 Airsec Ind Sa PACKAGING FOR PRODUCTS REQUIRING THE USE OF A DEHYDRANT.
JPH0471560A (en) 1990-07-10 1992-03-06 Mect Corp Packing body
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE4140689B4 (en) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
DE69332240T2 (en) 1992-06-12 2003-04-10 Teijin Ltd., Osaka ULTRA FINE POWDER FOR INHALATION AND PRODUCTION
ES2159524T3 (en) 1992-06-12 2001-10-16 Teijin Ltd PHARMACEUTICAL PREPARATION TO BE ADMINISTERED INSIDE THE RESPIRATORY ROADS.
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
AU670627B2 (en) 1992-09-09 1996-07-25 Fisons Plc Pharmaceutical packaging
SE9203743D0 (en) 1992-12-11 1992-12-11 Astra Ab EFFICIENT USE
UA27961C2 (en) 1992-12-18 2000-10-16 Шерінг Корпорейшн Inhalator for powder medicines
US5441060A (en) 1993-02-08 1995-08-15 Duke University Dry powder delivery system
US5730785A (en) 1993-04-01 1998-03-24 Multisorb Technologies, Inc. Desiccant canister for desiccants and other particulate material
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (en) 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
DE4323636A1 (en) 1993-07-15 1995-01-19 Hoechst Ag Pharmaceutical preparations from coated, poorly water-soluble pharmaceutical substances for inhalation pharmaceutical forms and processes for their preparation
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5503662A (en) 1994-03-29 1996-04-02 Multiform Desiccants, Inc. Canister with porous plastic ends
FI95441C (en) 1994-05-31 1996-02-12 Leiras Oy Inhaler drug chamber
US5641425A (en) 1994-09-08 1997-06-24 Multiform Desiccants, Inc. Oxygen absorbing composition
US6156231A (en) 1994-09-08 2000-12-05 Multisorb Technologies, Inc. Oxygen absorbing composition with cover layer
AR002009A1 (en) 1994-12-22 1998-01-07 Astra Ab PHARMACEUTICAL COMPOSITION, PROCEDURE FOR THE MANUFACTURE OF A PROLIPOSOMA POWDER AS USED IN SUCH COMPOSITION, PROCEDURE FOR LAMANUFACTURE OF SUCH COMPOSITION, USE OF SUCH PHARMACEUTICAL COMPOSITION IN THE MANUFACTURE OF A DISPOSAL MEDICINAL PRODUCT.
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
NZ306829A (en) 1995-04-19 1997-12-19 Capitol Vial Inc Dessicant material included in a closed container
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6103141A (en) 1997-01-23 2000-08-15 Multisorb Technologies, Inc. Desiccant deposit
WO1998040169A1 (en) 1997-03-14 1998-09-17 The University Of Houston Methods for making fluorinated surface modifying agents, methods of using same and products made using same
US5985415A (en) 1997-11-17 1999-11-16 Reconnx, Inc. Finger joint architecture for wood products, and method and apparatus for formation thereof
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
EP1290930B1 (en) 1998-02-05 2005-09-14 E.I. Du Pont De Nemours And Company Process for germinating plant seeds and growing a seedling
CO5021210A1 (en) 1998-04-18 2001-03-27 Glaxo Group Ltd PHARMACEUTICAL FORMULATION IN AEROSOL
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DE59914603D1 (en) 1998-11-13 2008-02-14 Jagotec Ag Multidose dry powder inhaler with powder reservoir
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
IT1309592B1 (en) 1999-03-05 2002-01-24 Chiesi Farma Spa VEHICLE PARTICLES MODIFIED FOR USE IN THE PREPARATION OF PHARMACEUTICAL FORMULATIONS IN THE FORM OF POLYMERS FOR INHALATION AND
HUP0200185A3 (en) 1999-03-05 2006-07-28 Chiesi Farma Spa Improved powdery pharmaceutical compositions for inhalation
US6303991B1 (en) 1999-05-27 2001-10-16 Fci Americas Technology, Inc. Electronic package and contact therefor
USD440874S1 (en) 1999-07-29 2001-04-24 The Gillette Company Container
CZ20021198A3 (en) 1999-10-11 2002-09-11 Ml Laboratories Plc Device for administering a medicament having surface treatment resistant to moisture
DE19957802A1 (en) 1999-12-01 2001-06-07 Trw Repa Gmbh Belt retractor system
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
JP2003531123A (en) 2000-04-13 2003-10-21 イノバータ・バイオミッド・リミテッド Medicine
PE20011227A1 (en) 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
JP2004501032A (en) 2000-05-15 2004-01-15 グラクソ　グループ　リミテッド Aerosol MDI cover containing desiccant
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
AU2001270074A1 (en) 2000-06-22 2002-01-02 Glaxo Group Limited Method and package for storing a pressurized container containing a drug
CN1294141C (en) 2000-08-05 2007-01-10 葛兰素集团有限公司 6.alpha., 9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
DE10056855A1 (en) 2000-11-16 2002-05-29 Lohmann Therapie Syst Lts Product, e.g. pharmaceutical, consisting of a laminate comprising a moisture- and/or oxygen-sensitive layer and a moisture- and/or oxygen-absorbing layer in air- and moisture-impermeable packaging
EP2292212A3 (en) 2000-11-30 2012-08-08 Vectura Limited Method of making particles for use in a pharmaceutical composition
PT2283817T (en) 2000-11-30 2016-08-22 Vectura Ltd Method of making particles for use in a pharmaceutical composition
EP1243524A3 (en) 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
EP1241110A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
DE10126924A1 (en) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalation capsule contains powdered mixture of tiotropium and auxiliary, for treating asthma or chronic obstructive pulmonary disease, having capsule material of low moisture content to improve stability
KR100912324B1 (en) * 2001-09-14 2009-08-14 글락소 그룹 리미티드 Penethanolamine Derivatives for the Treatment of Respiratory Diseases
AU2002351271A1 (en) 2001-12-21 2003-07-24 Nektar Therapeutics Capsule package with moisture barrier
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
US20030203141A1 (en) 2002-04-25 2003-10-30 Blum John B. Blister package
US20060269708A1 (en) 2002-06-20 2006-11-30 Rick Merical Films having a desiccant material incorporated therein and methods of use and manufacture
US20040131805A1 (en) 2002-06-20 2004-07-08 Merical Rick L. Films having a desiccant material incorporated therein and methods of use and manufacture
US20030235664A1 (en) 2002-06-20 2003-12-25 Rick Merical Films having a desiccant material incorporated therein and methods of use and manufacture
US8003179B2 (en) 2002-06-20 2011-08-23 Alcan Packaging Flexible France Films having a desiccant material incorporated therein and methods of use and manufacture
WO2004101390A1 (en) 2003-05-19 2004-11-25 Stopak (Pty) Ltd Dessicant container
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
SE527191C2 (en) 2003-06-19 2006-01-17 Microdrug Ag Inhaler device and combined doses of tiotropium and fluticasone
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
CN1819817A (en) 2003-07-09 2006-08-16 株式会社钟根堂 The solid dispersion of tacrolimus
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
JP2009514779A (en) * 2003-07-11 2009-04-09 グラクソ グループ リミテッド Pharmaceutical formulation
WO2005004846A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
US20050072958A1 (en) 2003-10-02 2005-04-07 Thomas Powers Oxygen scavenger for low moisture environment and methods of using the same
AP2007004238A0 (en) 2003-10-14 2007-12-31 Glaxo Group Ltd Muscarinic acetycholine receptor antagonists
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
SE0303270L (en) 2003-12-03 2005-06-04 Microdrug Ag Method of administration of tiotropium
SE0303570L (en) 2003-12-03 2005-06-04 Microdrug Ag Moisture-sensitive medical product
BRPI0417097A (en) 2003-12-03 2007-03-13 Microdrug Ag pre-metered dry powder inhaler for moisture sensitive medicines
SE0303569L (en) 2003-12-03 2005-06-04 Microdrug Ag DPI for delivery of moisture-sensitive drugs
SE0303269L (en) 2003-12-03 2005-06-04 Microdrug Ag Medical product
AU2004294889B2 (en) 2003-12-03 2010-08-26 Boehringer Ingelheim International Gmbh Medical product containing tiotropium
GB2410192B (en) 2004-01-23 2005-12-07 Eg Technology Ltd An inhaler
AR050902A1 (en) 2004-04-27 2006-12-06 Glaxo Group Ltd QUINUCLIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USOPRATION TO PREPARE SUCH COMPOSITION
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
RU2385156C2 (en) 2004-05-31 2010-03-27 Лабораториос Альмираль С.А. Combinations containing antimuscarine agents and corticosteroids
ES2257152B1 (en) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
SE530006C2 (en) 2004-06-18 2008-02-05 Mederio Ag Inhaler using tub
SE0401654D0 (en) 2004-06-24 2004-06-24 Astrazeneca Ab A support structure for a drug
GB0416397D0 (en) 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
CA2583995A1 (en) 2004-10-21 2006-05-04 Boehringer Ingelheim International Gmbh Blister for inhalers
US7501011B2 (en) 2004-11-09 2009-03-10 Multisorb Technologies, Inc. Humidity control device
SE0402976L (en) 2004-12-03 2006-06-04 Mederio Ag Medical product
PE20060826A1 (en) 2004-12-06 2006-10-08 Smithkline Beecham Corp OLEOPHINIC DERIVATIVE OF 8-AZONIABICICLO [3.2.1] OCTANE AND THE PHARMACEUTICAL COMBINATION THAT INCLUDES IT
PE20061162A1 (en) 2004-12-06 2006-10-14 Smithkline Beecham Corp COMPOUNDS OLEFINIC DERIVATIVES OF 8-AZONIABICICLO [3.2.1] OCTANES
ATE422852T1 (en) 2004-12-08 2009-03-15 Perfecseal Inc STERILIZABLE HIGH OXYGEN BARRIER PACKAGE
EP1835897A2 (en) 2004-12-27 2007-09-26 King Pharmaceuticals Research and Development Inc. Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions
US20060144733A1 (en) 2004-12-30 2006-07-06 3M Innovative Properties Company Container assembly and method for humidity control
CN101155590A (en) 2005-02-10 2008-04-02 葛兰素集团有限公司 Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
WO2006086130A2 (en) 2005-02-10 2006-08-17 Glaxo Group Limited Process for crystallizing lactose particles for use in pharmaceutical formulations
DE202005002409U1 (en) 2005-02-15 2005-07-07 Microdrug Ag Medicinal product containing tiotropium, for treatment of asthma or chronic obstructive pulmonary disease, comprising powdered drug and carrier in container with high protection dry seal, for use in powder inhaler
DE202005004659U1 (en) 2005-03-22 2005-07-07 Microdrug Ag Predosed dry powder inhaler containing tiotropium, for treatment of respiratory tract diseases such as asthma, with powdered drug and carrier enclosed in container with high protection dry seal
GB0507165D0 (en) 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
JP4659523B2 (en) 2005-04-26 2011-03-30 共同印刷株式会社 Blister film and blister packaging container
WO2006124556A2 (en) 2005-05-13 2006-11-23 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
DE102005022862A1 (en) 2005-05-18 2006-12-14 Airsec S.A.S Capsules for inhalers
US20060278965A1 (en) 2005-06-10 2006-12-14 Foust Donald F Hermetically sealed package and methods of making the same
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
CA2623658A1 (en) 2005-09-28 2007-04-05 Mederio Ag Inhaler device for moisture sensitive drugs and method of operating an inhaler device
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
PL1780005T3 (en) 2005-10-18 2009-07-31 Alcan Tech & Management Ltd Coldformable laminate for blister bottom sheet
EP1787800A1 (en) 2005-11-17 2007-05-23 Alcan Technology &amp; Management Ltd. Cold-workable laminate used for the base of a blister pack
AR058289A1 (en) 2005-12-12 2008-01-30 Glaxo Group Ltd COLLECTOR TO BE USED IN MEDICINAL DISPENSER
EP1990052B1 (en) 2006-02-27 2012-05-16 Takeda Pharmaceutical Company Limited Pharmaceutical package comprising 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or 2-cyclopropyl-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl and a desiccant.
KR100764640B1 (en) 2006-03-08 2007-10-10 세원셀론텍(주) Adipose tissue repair kit
WO2007109606A2 (en) 2006-03-17 2007-09-27 Csp Technologies, Inc. Moisture-tight primary packaging for a dry powder inhaler
AR060039A1 (en) * 2006-03-22 2008-05-21 3M Innovative Properties Co NEW FORMULATIONS
US20090123391A1 (en) * 2006-03-22 2009-05-14 3M Innovative Properties Company Novel Formulations
US20090169586A1 (en) 2006-03-24 2009-07-02 Ian Simon Tracton Stable packaged dosage form and process therefor
WO2007135024A1 (en) * 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh New long-acting drug combinations for the treatment of respiratory diseases
GB0615108D0 (en) 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
RU2448026C2 (en) 2006-08-03 2012-04-20 Мерк Патент Гмбх Package with pharmaceutical preparations
US20090291146A1 (en) 2006-08-09 2009-11-26 Glaxo Group Limited Process for manufacturing lactose
US20090298742A1 (en) 2006-08-09 2009-12-03 Glaxo Group Limited Process for manufacturing lactose
FI20065636A0 (en) 2006-10-04 2006-10-04 Lab Pharma Ltd Desiccant system for controlling the moisture of inhalable powders
EP2086641A2 (en) 2006-10-26 2009-08-12 Boehringer Ingelheim International GmbH Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
US20080178559A1 (en) 2007-01-26 2008-07-31 Multisorb Technologies, Inc. Sorbent Packaging
US8034739B2 (en) 2007-03-29 2011-10-11 Multisorb Technologies, Inc. Method for selecting adsorptive composite barriers for packaging applications
US7549272B2 (en) 2007-04-16 2009-06-23 Multisorb Technologies, Inc. Sorbent canister with beveled edges
WO2008135570A1 (en) 2007-05-07 2008-11-13 Airsec Container with moisture control capacity
UY31233A1 (en) 2007-07-21 2009-03-02 PACKING UNITS WITH A DESIRING AGENT
UY31235A1 (en) 2007-07-21 2009-03-02 NEW PULVERULENT DRUGS CONTAINING TIOTROPY AND SALMETEROL, AS WELL AS LACTOSE AS EXCIPIENT
WO2009029029A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab Inhaler for powdered substances with desiccant compartment
BRPI0816255A2 (en) 2007-09-12 2015-03-17 Glaxo Group Ltd Pharmaceutical product, use of the product, method for the prophylaxis or treatment of diseases, and pharmaceutically acceptable composition.
EP2080523A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
EP2254630A1 (en) 2008-02-20 2010-12-01 Boehringer Ingelheim International GmbH Powder inhalers
JP4983657B2 (en) 2008-03-11 2012-07-25 富士通株式会社 E-mail management program, recording medium recording the program, communication terminal, and e-mail management method
EP2127628A1 (en) 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
US9095324B2 (en) 2008-06-20 2015-08-04 Boston Scientific Scimed, Inc. Package assembly
US8293748B2 (en) 2008-10-02 2012-10-23 Respivert Ltd. p38 MAP kinase inhibitors
UY32297A (en) 2008-12-22 2010-05-31 Almirall Sa MESILATE SALT OF 5- (2 - {[6- (2,2-DIFLUORO-2-PHENYLITOXI) HEXIL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONA AS A RECEIVER AGONIST B (BETA ) 2 ACRENERGIC
ES2994042T3 (en) 2009-02-26 2025-01-16 Glaxo Group Ltd Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
WO2010097114A1 (en) 2009-02-26 2010-09-02 Glaxo Group Limited Novel combination of therapeutic agents
EP2432535B1 (en) 2009-05-18 2017-09-20 Adamis Pharmaceuticals Corporation Dry powder inhalers
DK2277799T3 (en) 2009-07-23 2012-05-21 Airsec Sas Hydrated moisturizing agent and process for its preparation
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2954888A1 (en) 2010-08-31 2015-12-16 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
BR112013031572A2 (en) 2011-06-08 2017-03-21 Glaxo Group Ltd pharmaceutical combination product, and dry powder inhaler.
AU2012266540A1 (en) 2011-06-08 2014-01-09 Glaxo Group Limited Dry powder inhaler compositions comprising umeclidinium
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239932A1 (en) * 2003-07-11 2006-10-26 Monteith Michael J Pharmaceutical formulations comprising magnesium stearate

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
EP3335707A1 (en) * 2009-12-01 2018-06-20 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EP3335707B1 (en) 2009-12-01 2024-04-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US9750726B2 (en) 2009-12-01 2017-09-05 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EP2506844B1 (en) 2009-12-01 2017-12-20 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
WO2011067212A1 (en) * 2009-12-01 2011-06-09 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EA023839B1 (en) * 2009-12-01 2016-07-29 Глаксо Груп Лимитед Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
US11090294B2 (en) 2009-12-01 2021-08-17 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EP4454645A1 (en) * 2009-12-01 2024-10-30 Glaxo Group Limited Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EP2611423B1 (en) 2010-08-31 2015-06-24 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
WO2012028663A1 (en) * 2010-08-31 2012-03-08 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
US20130157991A1 (en) * 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
EP2954888A1 (en) * 2010-08-31 2015-12-16 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JP2014516062A (en) * 2011-06-08 2014-07-07 グラクソ グループ リミテッド Combinations containing umecridinium and corticosteroids
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
US9795561B2 (en) 2012-12-17 2017-10-24 Glaxo Group Limited Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
WO2014155134A1 (en) 2013-03-28 2014-10-02 Vectura Limited Use of stearate in an inhalable formulation
EP2957553A1 (en) * 2014-06-16 2015-12-23 Arven Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations of vilanterol
EP2957551B1 (en) 2014-06-16 2020-01-15 Arven Ilac Sanayi Ve Ticaret A.S. Dry powder formulations comprising vilanterol
EP2957552B1 (en) 2014-06-16 2020-01-22 Arven Ilac Sanayi Ve Ticaret A.S. Vilanterol formulations
EP2957550A1 (en) * 2014-06-16 2015-12-23 Arven Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations comprising vilanterol
EP2957551A1 (en) * 2014-06-16 2015-12-23 Arven Ilac Sanayi Ve Ticaret A.S. Dry powder formulations comprising vilanterol
EP2957552A1 (en) * 2014-06-16 2015-12-23 Arven Ilac Sanayi Ve Ticaret A.S. Vilanterol formulations
US20170266135A1 (en) * 2014-07-09 2017-09-21 Arven Ilac Sanayi Ve Ticaret A.S. Process for preparing the inhalation formulations
US20170143626A1 (en) * 2014-07-09 2017-05-25 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A PROCESS FOR THE PREPARATION of DRY POWDER FORMULATIONS
US20170143625A1 (en) * 2014-07-09 2017-05-25 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Novel process for the preparation of dry powder formulations
WO2016005440A1 (en) * 2014-07-09 2016-01-14 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of dry powder formulations
WO2016005434A1 (en) * 2014-07-09 2016-01-14 Arven Ilac Sanayi Ve Ticaret A.S. Novel process for the preparation of dry powder formulations

Also Published As

Publication number Publication date
HRP20191257T1 (en) 2019-10-18
PT2400950T (en) 2019-08-29
ES2739352T3 (en) 2020-01-30
US11116721B2 (en) 2021-09-14
ES2994042T3 (en) 2025-01-16
PL3578169T3 (en) 2024-09-02
EP2400950A1 (en) 2012-01-04
LT2400950T (en) 2019-08-26
US20110319371A1 (en) 2011-12-29
SI3578169T1 (en) 2024-09-30
EP2400950B1 (en) 2019-05-22
PT3578169T (en) 2024-07-29
PL2400950T3 (en) 2019-12-31
HRP20241000T3 (en) 2024-10-25
EP4403231A3 (en) 2024-10-23
JP5809985B2 (en) 2015-11-11
HUE067290T2 (en) 2024-10-28
SI2400950T1 (en) 2019-09-30
HUE045917T2 (en) 2020-01-28
EP3578169B1 (en) 2024-06-26
JP2012518663A (en) 2012-08-16
CY1121914T1 (en) 2020-10-14
DK3578169T3 (en) 2024-07-22
LT3578169T (en) 2024-08-26
EP3578169A1 (en) 2019-12-11
FI3578169T3 (en) 2024-09-18
DK2400950T3 (en) 2019-07-29
EP4403231A2 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
US11116721B2 (en) Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
US11090294B2 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
EP2717867A1 (en) Dry powder inhaler compositions comprising umeclidinium
WO2010097114A1 (en) Novel combination of therapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09779096

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13148982

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011551415

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2009779096

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE